Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis

This publication has 26 references indexed in Scilit:

• High expression of RelA/p65 is associated with activation of nuclear factor-κB-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis
  British Journal of Cancer, 2007
• Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug
  Nature Biotechnology, 2007
• Cancer Statistics, 2007
  CA: A Cancer Journal for Clinicians, 2007
• Anticancer activities of histone deacetylase inhibitors
  Nature Reviews Drug Discovery, 2006
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
  Nature Reviews Cancer, 2006
• Epigenetic therapy of cancer: past, present and future
  Nature Reviews Drug Discovery, 2006
• CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTS
  Annual Review of Pharmacology and Toxicology, 2005
• Molecular-pathological prognostic factors of gastric cancer: a review
  Gastric Cancer, 2005
• In vivo and in vitro antitumor activity of butyroyloxymethyl‐diethyl phosphate (AN‐7), a histone deacetylase inhibitor, in human prostate cancer
  International Journal of Cancer, 2005
• Trends in the incidence of gastric cancer in Japan and their associations with Helicobacter pylori infection and gastric mucosal atrophy
  Gastric Cancer, 2004